ProShare Advisors’s ImageneBio Inc IMA Stock Holding History

ProShare Advisors’s Portfolio IMA Stock Details IMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-926	Closed	-$138K	–	2247
2021 Q4	$138K	Buy	+926	New	+$150K	﹤0.01%	2147

Other funds holding IMA

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ProShare Advisors's IMA Position: Q1 2022 in Review

ProShare Advisors sold out of ImageneBio Inc (IMA) in Q1 2022, closing a stake of 926 shares — an estimated $138K sold.

ProShare Advisors first reported a position in IMA in Q4 2021 and held it in 1 quarter. The position peaked at $138K in Q4 2021. 48 funds tracked by Wall St. Rank hold IMA as of Q1 2022.

ProShare Advisors reported no remaining ImageneBio Inc position as of Q1 2022 after selling out during the quarter.
ProShare Advisors sold 926 ImageneBio Inc shares in Q1 2022, an estimated $138K.
ProShare Advisors first reported a position in ImageneBio Inc in Q4 2021 and held it in 1 quarter.
ProShare Advisors's ImageneBio Inc position peaked at $138K in Q4 2021.
48 funds tracked by Wall St. Rank held ImageneBio Inc as of Q1 2022.

Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.